U.S. officials, including Secretary of State Mike Pompeo, have accused Iran of orchestrating devastating strikes on Saudi oil installations over the weekend.Politicsread more
Rosengren was one of two central bank officials to vote against Wednesday's quarter-point rate reduction, and explained in a speech to the Stern School of Business at New York...Economyread more
"The president is right to make this the center point of the rising and sustained trade conflict," says Sen. Chris Coons.Politicsread more
More than 400 Chinese products will be temporarily exempted from tariffs that President Donald Trump's administration imposed last year.China Economyread more
"We're gonna take this meeting by meeting. We're not on a preset course," Clarida told CNBC's Sara Eisen during an interview Friday on "Squawk on the Street."The Fedread more
Netflix CEO Reed Hastings admitted that it's a "whole new world starting in November," with the launch of Apple TV+, Disney+ and other new streaming services.Technologyread more
President Donald Trump sarcastically tweeted that New York City "is devastated" by Mayor Bill de Blasio's exit from the 2020 presidential race. Two other Democratic mayors,...2020 Electionsread more
The United Auto Workers union and General Motors are making progress on their labor contract talks, however there remain "many" outstanding issues, according to a union leader...Autosread more
Democratic presidential candidate Elizabeth Warren has been given more than one opportunity over the past two weeks to clarify her response to a key question about her...Politicsread more
Protesters across the world Friday joined in on demonstrations to demand action on climate change.Environmentread more
Apple will get a taste of whether upgraded features on the new iPhone 11 are enough to lure shoppers to retail stores around the world as the new smartphones officially hit...Technologyread more
(Adds background, comment from pharmacy CEO)
Aug 28 (Reuters) - The U.S. Food and Drugs Administration said on Wednesday it was expanding its investigation into impurities in U.S. generic drugs beyond a class of medicines for high blood pressure known as angiotensin II receptor blockers (ARBs).
The agency did not specify which types of additional drugs it was looking at, but said it was testing samples of other medicines with similar manufacturing processes to those in which concerning impurities have been discovered.
Since last summer, the FDA has been conducting a major investigation to address the presence of certain impurities that could cause cancer in ARBs such as valsartan, the generic of Novartis' Diovan. Some generic ARBs, such as valsartan and irbesartan, have been recalled.
The recalls began last year after regulators said ingredients used by Chinese manufacturer Zhejiang Huahai Pharmaceuticals Co to produce valsartan contained potentially cancer-causing impurities.
Since then, generic drugmakers such as Mylan NV, Teva Pharmaceutical Industries and Novartis' Sandoz have recalled products containing the tainted ingredients.
It is difficult to know which classes of drugs the FDA is testing in its expanded investigation because companies keep their manufacturing processes secret, according to David Light, chief executive of Valisure, an online pharmacy that chemically tests the medication its sells for flaws.
"Could this be happening in a variety of other drugs? Absolutely," Light said. (Reporting by Michael Erman in New York and Manas Mishra in Bengaluru; Editing by Arun Koyyur and Bill Berkrot)